Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Cash & Equivalents (2016 - 2025)

Dare Bioscience (DARE) has disclosed Cash & Equivalents for 11 consecutive years, with $23.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 105.43% year-over-year to $23.1 million, compared with a TTM value of $23.1 million through Sep 2025, up 105.43%, and an annual FY2024 reading of $15.7 million, up 49.85% over the prior year.
  • Cash & Equivalents was $23.1 million for Q3 2025 at Dare Bioscience, up from $5.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $51.7 million in Q4 2021 and bottomed at $3.6 million in Q1 2024.
  • Average Cash & Equivalents over 5 years is $21.2 million, with a median of $15.7 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents soared 1006.64% in 2021, then plummeted 81.61% in 2024.
  • Year by year, Cash & Equivalents stood at $51.7 million in 2021, then tumbled by 32.91% to $34.7 million in 2022, then crashed by 69.78% to $10.5 million in 2023, then soared by 49.85% to $15.7 million in 2024, then skyrocketed by 46.99% to $23.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for DARE at $23.1 million in Q3 2025, $5.0 million in Q2 2025, and $10.3 million in Q1 2025.